Neuropathologic changes in Alzheimer's disease.
暂无分享,去创建一个
[1] B. Varnum,et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.
[2] O'Banion Mk. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. , 1999 .
[3] M. O’Banion,et al. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. , 1999, Critical reviews in neurobiology.
[4] J. Rogers. Inflammation as a pathogenic mechanism in Alzheimer's disease. , 1995, Arzneimittel-Forschung.
[5] K. Prasad,et al. Risk Factors for Alzheimer’s Disease: Role of Multiple Antioxidants, Non-Steroidal Anti-inflammatory and Cholinergic Agents Alone or in Combination in Prevention and Treatment , 2002, Journal of the American College of Nutrition.
[6] H. Herschman,et al. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. , 1992, The Journal of biological chemistry.
[7] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[8] E. Sigurdsson,et al. A safer vaccine for Alzheimer’s disease? , 2002, Neurobiology of Aging.
[9] B Frangione,et al. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. , 2001, The American journal of pathology.
[10] W. Danysz,et al. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. , 2000, Life sciences.
[11] G. Wenk,et al. A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. , 2002, European journal of pharmacology.
[12] V. Winn,et al. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[13] K. Ashe,et al. Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.
[14] B. Hauss-Wegrzyniak,et al. Chronic Brain Inflammation Results in Cell Loss in the Entorhinal Cortex and Impaired LTP in Perforant Path-Granule Cell Synapses , 2002, Experimental Neurology.
[15] V. Winn,et al. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. , 1991, The Journal of biological chemistry.
[16] Roger N Gunn,et al. In-vivo measurement of activated microglia in dementia , 2001, The Lancet.
[17] G. Wenk,et al. Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. , 2000, European journal of pharmacology.
[18] Rong Wang,et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.
[19] G. Wenk,et al. Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats , 1999, Neuroscience.
[20] G. Wenk,et al. The effects of a novel NSAID on chronic neuroinflammation are age dependent☆ , 1999, Neurobiology of Aging.
[21] P. Kelly,et al. Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis , 2002, The Journal of Neuroscience.
[22] C. Lemere,et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. , 2001, The American journal of pathology.
[23] P. Aisen. Anti-inflammatory agents in Alzheimer’s disease , 2002, Current neurology and neuroscience reports.
[24] C. Plata-salamán,et al. Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.
[25] P. Zandi,et al. Do NSAIDs prevent Alzheimer’s disease? And, if so, why? The epidemiological evidence , 2001, Neurobiology of Aging.
[26] D. Selkoe,et al. Deciphering the genetic basis of Alzheimer's disease. , 2002, Annual review of genomics and human genetics.
[27] L. Rowland,et al. Merritt's textbook of neurology , 1995 .